Taking stock of the drug industry, from the lab to the medicine chestFebruary 27, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer STAT+ | FDA is petitioned to boost enforcement of trial sponsors that fail to register studies or report results Advocates want the FDA to take steps to boost its enforcement of wayward trial sponsors and investigators that fail to report results. By Ed Silverman STAT+ | FDA's Billy Dunn, key figure in approval of Aduhelm, to leave agency Billy Dunn is leaving the Food and Drug Administration after more than 15 years at the agency, STAT has learned. By Adam Feuerstein and Damian Garde STAT+ | U.S. trade rep urged not to sanction countries if they sidestep patents on Vertex cystic fibrosis drugs Advocacy groups are asking the U.S. trade representative not to sanction governments if they grant requests from cystic fibrosis patients. By Ed Silverman Molly Ferguson/STAT STAT+ | For Cytokinetics, an FDA rejection of its heart drug would help, not hinder Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation. By Adam Feuerstein STAT+ | How Eric Lander's sharp elbows spurred MIT's Nancy Hopkins to start a gender revolution "These powerful men could do whatever they want, no matter how egregious it was," Nancy Hopkins said of being ousted from a biology course. By Kate Zernike STAT+ | Hospital systems' investment income perked up at end of 2022 Large hospital systems' investments rebounded heavily in the final quarter of 2022, according to a new STAT analysis of financial filings. By Bob Herman and Tara Bannow More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments